Overweight Clinical Trial
— NExTOfficial title:
NExT (Nutrition and Exercise Cancer Survivor Trial)
Verified date | August 2019 |
Source | Ohio State University Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized phase II trial will enroll overweight cancer survivors. Subjects in both groups will be educated to follow a diet pattern similar to what is recommended by the Dietary Guidelines for Americans and the American Institute for Cancer Research (DGA/AICR) but one group will also receive 18 ounces of lean beef for incorporation into a healthy diet. Subjects will be encouraged to exercise regularly and activity will be monitored throughout the study. Nutrition and exercise may help cancer survivors successfully maintain improved dietary patterns, body composition, and physical activity efforts and consumption of beef may favorably impact lean body mass and specific nutritional outcomes.
Status | Completed |
Enrollment | 82 |
Est. completion date | June 1, 2019 |
Est. primary completion date | June 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Have a body mass index (BMI) >= 25 kg/m^2 - Be non-vegetarian/non-vegan, and have no concerns with beef consumption - Have completed active curative therapy for cancer within the past 36 months (i.e., surgery, chemotherapy, or radiation); ongoing hormone therapy is acceptable - Voluntarily provide consent, Health Insurance Portability and Accountability Act (HIPPA) authorization form, and consent from primary care provider (PCP) or treating oncologist - Not be planning to travel for more than 3 consecutive weeks during the intervention period - Agree to refrain from all nutritional supplements, herbal supplements, and botanical supplements aside from those prescribed by a physician for the duration of the study Exclusion Criteria: - Are cognitively unable to consent or have physical or mental limitations that would prevent full participation in the program - Are vegan or those unwilling to consume 11-18 ounces (oz) of beef per week - Have pre-existing medical conditions that preclude unsupervised physical activity (i.e., severe orthopedic conditions, impending hip or knee replacement, paralysis, unstable angina, dementia, recent history of myocardial infarction, congestive heart failure, pulmonary conditions requiring oxygen, or hospitalization in past 6 months) - Have had cancer treatment that significantly impacts digestion, metabolism, or food intake (e.g., surgical loss of esophagus, stomach, or colon, pancreas dysfunction, or brain surgery that alters cognition, etc.) - Report meeting the recommendations for physical activity (> 60 minutes per day, most days per week) and already meet the majority of dietary guidelines as assessed by a telephone screener - Are prescribed medication that do not allow for increased intake of fruits and vegetables - Have recently (< 3 months) started a statin or other lipid lowering medication; participants who report that they are changing a lipid lowering drug dose or drug type during the recruitment period will also be excluded; participants who have been stable on a lipid-lowering medication for at least 3 months may participate; well-controlled diabetics (type I or II) may participate - Have been diagnosed with active metabolic or digestive illnesses (i.e., Celiac disease, irritable bowel syndrome [IBS], renal insufficiency, hepatic insufficiency) - Are pregnant or are planning to become pregnant during the study |
Country | Name | City | State |
---|---|---|---|
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio State University Comprehensive Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adherence to either the DGA/AICR group or the DGA/AICR + Beef group | Participants will keep both 7 day diet records periodically through out the study as well as a daily log of beef consumption | Up to 12 months | |
Primary | Change in body composition | Change in body composition will be assessed by dual X-ray absorptiometry (iDXA) | Up to 12 months | |
Primary | Change in blood pressure | Trained personnel will use a sphygomanometer to assess blood pressure | Baseline up to 12 months | |
Primary | Change in body mass index (BMI) | Weight and height will be combined to report BMI in kg/m^2. | Baseline up to 12 months | |
Primary | Change in dietary carotenoid intake | Assessed by Raman spectroscopy | Baseline up to 12 months | |
Primary | Change in blood carotenoids | Assessed by High Pressure Liquid Chromatography | Up to 12 months | |
Primary | Change in physical performance assessed by timed performance-related mobility tasks | Physical performance will be measured using the 40 M walk test | Baseline up to 12 months | |
Primary | Change in physical performance | Assessed by a standardized stair climb test | Up to 12 months | |
Primary | Dietary intake patterns | Will be assessed using diet logs maintained throughout the intervention and graphical food frequency questionnaire (FFQ). This FFQ automatically calculates the Healthy Eating Index 2010. Will use previous 30-day intake for all FFQs to assess dietary patterns. To determine protein balance, will use a 7-day diet record prior to a 24-hr urine collection. | Up to 6 months | |
Primary | Adherence to classes | Descriptive statistics will be generated using attendance forms | Up to 12 months | |
Primary | Change in fasting glucose | A fasting blood sample will be used to measure glucose at three time points | Up to 12 months | |
Primary | Change in lipoprotein profiles | A fasting blood sample will be used to assess serum lipoprotein profile | Up to 12 months | |
Primary | Daily physical activity (steps per day) | Each participants daily FitBit data will be downloaded to a secure spreadsheet | up to 12 months | |
Secondary | Health related quality of life | Measured at all three time points using the Health Related Quality of Life (HR-QOL) questionnaire | Up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Terminated |
NCT03299881 -
Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss
|
N/A | |
Completed |
NCT02805478 -
Fat-Associated Cardiovascular Organ Dysfunction
|
||
Active, not recruiting |
NCT02558920 -
Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
|
||
Completed |
NCT03759743 -
Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject
|
N/A | |
Completed |
NCT03610958 -
Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.
|
N/A | |
Completed |
NCT03678766 -
CHARGE: Controlling Hunger and ReGulating Eating
|
N/A | |
Completed |
NCT04430465 -
Effects of Wholegrains on Children's Health (KORN)
|
N/A | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT05376865 -
Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers
|
N/A | |
Completed |
NCT03625427 -
Effect of Palmitoleic Acid on C-reactive Protein
|
N/A | |
Active, not recruiting |
NCT03435445 -
Online Platform for Healthy Weight Loss (POEmaS)
|
N/A | |
Enrolling by invitation |
NCT05576116 -
Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics
|
N/A | |
Recruiting |
NCT05249465 -
Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention
|
N/A | |
Active, not recruiting |
NCT06023095 -
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
|
Phase 1 | |
Completed |
NCT03648892 -
Brain Dopamine Function in Human Obesity
|
Early Phase 1 | |
Not yet recruiting |
NCT05751993 -
Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions
|
N/A | |
Recruiting |
NCT02887950 -
Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause
|
N/A | |
Completed |
NCT03097237 -
High Fiber Rye Foods for Weight and Body Fat Reduction
|
N/A | |
Terminated |
NCT02796144 -
MEtformin and Lorcaserin for WeighT Loss in Schizophrenia
|
Phase 4 |